Large gap with delayed quotes
|
Last quote
12/27/2024 -
20:00:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
25.54
+0.14
(
+0.55% )
|
25.54
|
7,500 |
25.56
|
6,900 |
Analysis date: 24.12.2024
Global Evaluation
Slightly positive
Slightly positive
The stock is classified in the slightly positive zone since 04.10.2024.
Interest
Weak
Weak
Weak interest since 13.12.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 13.12.2024 at a price of 24.84.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 08.10.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-5.56%
-5.56%
The four week relative underperformance versus SP500 is 5.56%.
Sensibility
Low
Low
The stock has been on the low-sensitivity level since 13.08.2024.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.71%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.52%.
Mkt Cap in $bn
14.88
14.88
With a market capitalization >$8bn, ROYALTY PHARMA is considered a large-cap stock.
G/PE Ratio
1.84
1.84
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
5.37
5.37
The estimated PE is for the year 2026.
LT Growth
6.37%
6.37%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
3.49%
3.49%
The twelve month estimated dividend yield represents 18.72% of earnings forecasts.
Beta
8
8
For 1% of index variation, the stock varies on average by 0.08%.
Correlation
0.07
0.07
Stock movements are totally independent of index variations.
Value at Risk
1.52
1.52
The value at risk is estimated at USD 1.52. The risk is therefore 6.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
20.11.2020
20.11.2020